OakChart

Aclaris Therapeutics Inc

ACRSHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

4.36+0.20 (4.94%)
2026-11-11 22:00 CET
Market cap
658.24 USD m
Revenue, TTM
6.40 USD m
Net income, TTM
-79.63 USD m
Free cash flow, TTM
-75.31 USD m
EPS diluted, TTM
-0.59
P/E
-
Compare

Price

ACRS against its 20, 50 and 200-day averages
2050200beat
3.004.005.006.004.5M9.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ACRSclose 4.3620-day 3.8250-day 4.52200-day 4.544.3652w high

34.0% under the 52-week high of 6.60 on 25 Aug 2026. 52-week low 2.10 on 11 Nov 2025. Last 15 sessions, 27.9% high to low

Volume 0.57× normal · the line is the 50-bar volume average

Profile

ACRS
52-week range, 50% of the way up
2.106.60

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

IndexRUT
Employees73
IPOOct 07, 2015
Beta0.93
ATR, 14d0.31
Rel volume0.57
Short float9.67%
Insider own24.55%
Inst own62.49%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap690.76M
Enterprise Value578.18M
Income-79.63M
Sales6.40M
Book/sh1.11
Cash/sh0.72
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees73
IPOOct 07, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S107.93
P/B3.94
P/C6.04
P/FCF-
EV/EBITDA-
EV/Sales90.34
Quick Ratio5.09
Current Ratio5.09
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.59
EPS next Y-0.67
EPS next Q-0.16
EPS this Y-13.36%
EPS next Y-11.79%
EPS next 5Y-10.88%
EPS past 3/5Y26.48% 15.08%
Sales past 3/5Y-35.93% 3.84%
EPS Y/Y TTM57.30%
Sales Y/Y TTM-59.34%
EPS Q/Q-3.86%
Sales Q/Q-55.11%
EarningsNov 05 BMO
EPS/Sales Surpr.25.79% 16.54%

Ownership

Insider Own24.55%
Insider Trans0.00%
Inst Own62.49%
Inst Trans4.30%
ROA-40.66%
ROE-55.51%
ROIC-47.43%
Gross Margin5.78%
Oper. Margin-1412.40%
Profit Margin-1244.09%
SMA2014.03%
SMA50-3.57%
SMA200-3.98%
Trades-

Technical

Shs Outstand150.83M
Shs Float119.67M
Short Float9.67%
Short Ratio4.09
Short Interest11.57M
52W High6.60 -34.01%
52W Low2.10 107.38%
Volatility8.41% 7.55%
ATR (14)0.31
RSI (14)57.46
Beta0.93
Rel Volume0.57
Avg Volume2.83M
Volume1,605,336

Performance

Perf Week18.34%
Perf Month25.50%
Perf Quarter-25.68%
Perf Half Y-14.44%
Perf YTD44.68%
Perf Year89.35%
Perf 3Y-8.41%
Perf 5Y-71.44%
Perf 10Y-80.81%
Recom1.15
Target Price10.92
Prev Close4.15
Price4.36
Change %4.94%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 01, 2026InitiatedCCanaccord GenuityBuy$10+129.6%
May 05, 2026InitiatedGGuggenheimBuy$12+175.5%
Apr 16, 2026InitiatedOOppenheimerOutperform$10+129.6%
Jul 10, 2025ResumedPPiper SandlerOverweight$6+37.8%
May 28, 2025InitiatedWWedbushOutperform$8+83.7%
Mar 18, 2025ResumedCCantor FitzgeraldOverweight
Dec 23, 2024UpgradeHH.C. WainwrightNeutral → Buy$20+359.2%
Nov 20, 2024UpgradeCCantor FitzgeraldNeutral → Overweight
Nov 19, 2024UpgradeLLeerink PartnersMarket Perform → Outperform$2 → $7+60.7%
Nov 19, 2024UpgradeJJefferiesHold → Buy$2 → $7+60.7%

Peers

Mkt cap
TickerCompanyMkt cap
UPBUpstream Bio Inc175.00M
GENBGenerate Biomedicines Inc1.73B
ALMSAlumis Inc884.41M
ATTOAttovia Therapeutics Inc769.12M
ANABAnaptysBio Inc1.46B
ZURAZura Bio Ltd137.75M
AVTXAvalo Therapeutics Inc491.78M
EVMNEvommune Inc312.84M
TRAXFirst Tracks Biotherapeutics Inc2.12B
CNTBConnect Biopharma Holdings Ltd43.17M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Leonard Braden Michael10% OwnerApr 23 '26Sale4.53300,0001,359,00013,950,000Apr 27 07:27 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DWASInvesco Dorsey Wright SmallCap Momentum ETFAUM: 391.13M

News

latest 14 of 198
  • Aclaris: Q3 Earnings Snapshot (Associated Press)
  • Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update (GlobeNewswire)
  • Aclaris Reports Positive Asthma, Eczema Drug Trial Results So, Why Is ACRS Stock Down Nearly 8%? (Stocktwits)
  • Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
  • Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Ra Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma (GlobeNewswire)
  • Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
  • Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) (GlobeNewswire)
  • Aclaris: Q2 Earnings Snapshot (Associated Press)
  • Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update (GlobeNewswire)
  • Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
  • Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference (GlobeNewswire)
  • Aclaris: Q1 Earnings Snapshot (Associated Press)
  • Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update (GlobeNewswire)
  • Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.120-0.162-0.1201.481.2712
2026Q22026-08-06-0.150-0.160-0.1511.631.3810
2026Q12026-05-07-0.150-0.158-0.1542.001.329
2025Q42026-02-26-0.160-0.145-0.1611.302.078
2025Q32025-11-06-0.120-0.136-0.1193.301.417
2025Q22025-08-07-0.130-0.133-0.1261.781.377
2025Q12025-05-08-0.120-0.152-0.1231.462.965
2024Q42025-02-27-1.010-0.287-1.0139.212.116
2024Q32024-11-06-0.110-0.006-0.1064.351.587
2024Q22024-08-07-0.150-0.205-0.1542.771.829
2024Q12024-05-07-0.240-0.286-0.2382.401.937
2023Q42024-02-27-0.020-0.344-0.02117.574.669
2023Q32023-11-06-0.410-0.480-0.4139.281.579
2023Q22023-08-07-0.420-0.450-0.4191.871.909
2023Q12023-05-08-0.420-0.437-0.4212.531.759
2022Q42023-02-23-0.410-0.445-0.4147.751.999

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3.900-3.460-3.9054.2322.59
2020FY-1.200-1.840-1.1996.486.29
2021FY-1.600-1.607-1.6026.767.05
2022FY-1.330-1.437-1.33329.7523.99
2023FY-1.270-1.612-1.26831.2518.34
2024FY-1.710-0.820-1.70918.7211.61
2025FY-0.530-0.526-0.5307.838.76
2026FY--0.601--6.37
2027FY--0.672--5.20
2028FY--0.723--6.47
2029FY--0.834--21.19
2030FY--0.771--81.90

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0611221.370.002.70
2026Q4S2026-11-0511111.380.002.70
2026Q4S2026-10-2911101.390.002.70
2026Q4S2026-10-2111001.350.002.70
2026Q4S2026-10-2011011.350.002.70
2026Q4S2026-10-1611221.350.002.70
2026Q4S2026-08-3110221.430.002.70
2026Q4S2026-08-079221.410.002.70
2026Q4S2026-08-069211.440.002.70
2026Q4S2026-07-229001.420.002.45
2026Q4S2026-07-219011.420.002.45
2026Q4S2026-05-129121.420.002.45
2026Q4S2026-05-089131.420.002.45
2026Q4S2026-05-079131.440.002.65

Estimate history

EPS, annual-2.44-4.033-3.905-1.199-1.602-1.333-1.268-1.709-0.53-0.5898
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.106-1.013-0.123-0.126-0.119-0.161-0.154-0.151-0.124
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.6836.1514.2276.4826.76129.75231.24918.727.8266.4
Period201720182019202020212022202320242025TTM
Sales, quarterly4.3469.2111.4551.7773.2991.2951.9961.6291.481
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual30.85741.21141.48645.10961.22866.68970.895107.85120.499150.825
Period201720182019202020212022202320242025MRQ
Shares, quarterly71.418107.85108.266108.329108.343120.499139.653139.824150.825
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue6.407.8318.7231.2529.756.766.484.236.15
Cost of Goods Sold Incl. D&A6.037.2815.2618.0811.964.715.134.054.33
Gross Profit0.370.543.4613.1717.792.051.350.171.82
Selling, General and Administrative Excl. Other90.7874.4253.29127.70102.9567.4349.8791.0085.33
Research and Development66.3752.6532.0998.3877.8143.8129.3463.7859.57
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-90.41-73.88-49.83-114.53-85.15-65.38-48.52-90.83-83.51
Interest Expense0.000.000.000.000.00---0.00
Unusual Expense0.102.5092.11-17.174.7024.342.3920.231.27
Net Income Before Taxes-79.63-64.92-132.06-88.85-86.91-90.86-51.34-113.54-82.10
Income Taxes0.000.000.00-0.370.000.00-0.180.000.00
Consolidated Net Income-79.63-64.92-132.06-88.48-86.91-90.86-51.15-113.54-82.10
Net Income From Continuing Operations-79.63-64.92-132.06-88.48-86.91-90.86-51.15-113.54-82.10
Net Income-79.63-64.92-132.06-88.48-86.91-90.86-51.02-161.35-132.74
EPS (Recurring)-0.53-0.52-0.87-1.44-1.28-1.30-1.16-3.56-4.01
EPS (Basic, Before Extraordinaries)-0.59-0.53-1.71-1.27-1.33-1.60-1.20-3.90-4.03
EPS (Diluted)-0.59-0.53-1.71-1.27-1.33-1.60-1.20-3.90-4.03
EBITDA-90.00-73.42-49.02-113.67-84.36-64.46-47.20-89.25-82.19
Non-Operating Income (Expense)10.8711.459.878.512.95-1.14-0.42-2.482.68
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.8112.3810.8616.2315.0414.068.1816.0813.08
Price To Sales Ratio122.8147.1410.242.3534.52122.0042.4618.4839.54
Gross Margin5.786.9318.4942.1459.8030.2920.814.0729.62
Operating Margin-1,412.40-943.97-266.17-366.50-286.21-967.08-748.52-2,148.83-1,357.63
Net Margin-1,244.09-829.58-705.48-283.15-292.11-1,343.96-787.03-3,817.22-2,157.99
Shares Outstanding150.83120.50107.8570.8966.6961.2345.1141.4941.21
Market Capitalization658.24658.24177.1574.381,050.26890.24277.6978.22302.52

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.481.632.001.293.301.781.469.21
Cost of Goods Sold Incl. D&A1.321.451.791.472.451.851.529.30
Gross Profit0.160.180.21-0.170.85-0.07-0.06-0.09
Selling, General and Administrative Excl. Other22.1024.1122.4022.1617.9016.8417.5213.98
Research and Development16.0718.0715.6616.5813.0311.4511.589.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-21.94-23.94-22.19-22.33-17.05-16.91-17.58-14.07
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.600.300.000.400.101.500.5085.61
Net Income Before Taxes-18.51-21.50-19.82-19.80-14.61-15.43-15.09-96.55
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-18.51-21.50-19.82-19.80-14.61-15.43-15.09-96.55
Net Income From Continuing Operations-18.51-21.50-19.82-19.80-14.61-15.43-15.09-96.55
Net Income-18.51-21.50-19.82-19.80-14.61-15.43-15.09-96.55
EPS (Recurring)-0.13-0.15-0.15-0.16-0.12-0.12-0.12-0.38
EPS (Basic, Before Extraordinaries)-0.12-0.15-0.15-0.16-0.12-0.13-0.12-1.01
EPS (Diluted)-0.12-0.15-0.15-0.16-0.12-0.13-0.12-1.01
EBITDA-21.84-23.83-22.09-22.23-16.84-16.69-17.46-13.93
Non-Operating Income (Expense)2.832.732.372.942.542.983.003.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.022.673.202.932.863.063.542.86
Price To Sales Ratio122.8191.8757.7347.1814.8010.3710.5312.63
Gross Margin10.8010.8010.42-13.4425.77-4.11-4.19-0.98
Operating Margin-1,481.70-1,469.49-1,111.82-1,724.63-516.79-951.49-1,208.52-152.75
Net Margin-1,249.83-1,320.14-993.19-1,528.57-442.98-868.26-1,036.77-1,048.22
Shares Outstanding150.83139.82139.65120.50108.34108.33108.27107.85
Market Capitalization658.24738.82452.23326.12205.83153.76165.12177.15

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments90.75113.59119.11217.57191.4154.1375.02167.97193.86
Short Term Receivables5.570.320.300.480.620.770.700.560.48
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.0012.049.4513.4912.992.598.0810.965.88
Total Current Assets96.32125.95128.86231.55205.0357.4983.80179.50200.22
Net Property, Plant & Equipment3.053.855.483.784.775.787.202.292.16
Total Investments and Advances60.6190.3062.7712.2434.240.000.000.0015.00
Intangible Assets--0.276.977.057.127.2025.7825.85
Deferred Tax Assets--2.153.36----2.10
Other Assets0.490.220.030.050.120.390.0968.000.28
Total Assets160.46220.33199.55257.96251.2170.7898.30275.57245.61
Short Term Debt Incl. Current Port. of LT Debt0.550.480.430.680.690.600.640.140.00
Accounts Payable13.164.698.8810.359.985.259.9211.687.82
Other Current Liabilities14.9426.4321.6510.9012.259.0211.8815.534.94
Total Current Liabilities28.6431.6030.9521.9422.9314.8722.4327.3412.76
Long Term Debt1.562.123.071.572.2013.553.5729.910.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities--2.153.730.370.370.550.552.65
Other Liabilities27.1731.066.2033.1028.374.351.832.644.94
Total Liabilities57.3864.7742.3760.3453.8733.1328.3960.4420.35
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity103.08155.55157.18197.62197.3437.6569.91215.12225.26
Total Shareholders Equity103.08155.55157.18197.62197.3437.6569.91215.12225.26
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity103.08155.55157.18197.62197.3437.6569.91215.12225.26
Total Liabilities & Stockholders Equity160.46220.33199.55257.96251.2170.7898.30275.57245.61
Book Value Per Share0.861.442.222.963.220.831.695.227.30
Tangible Book Value Per Share0.861.442.212.863.110.681.514.596.46
Full-Time Employees73649110577607716996
Price to Book Ratio3.751.360.484.784.517.751.121.423.11
Return on Assets-34.10-62.91-38.68-34.14-56.44-60.51-60.74-31.51-32.50
Return on Equity-50.20-84.46-49.88-44.01-77.33-95.12-79.67-37.29-34.72
Return on Invested Capital-62.04-83.76-55.21-43.63-45.54-99.64-219.59-54.17-30.42
Quick Ratio3.363.994.1610.558.943.873.746.5615.69
Current Ratio3.363.994.1610.558.943.873.746.5615.69

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-79.63-64.92-132.06-88.48-86.91-90.86-51.02-161.35-132.74
Depreciation0.410.450.810.860.800.921.326.411.88
Other Funds (Non Cash)11.9114.68100.260.2719.7439.1513.6061.2020.61
Funds from Operations-67.31-49.78-31.00-87.71-66.37-50.79-36.27-93.74-110.25
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-7.902.6710.929.39-1.20-1.34-2.36-2.709.44
Cash from Operating Activities-75.21-47.11-20.07-78.33-67.57-52.13-38.63-96.44-100.81
Capital Expenditures0.72-0.11-35.93-1.31-0.60-0.31-0.45-1.61-68.48
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-43.4149.31-33.8447.5313.23-167.326.8473.1177.84
Purchase of Investments-118.41-39.73-119.98-135.68-164.75-235.15-47.71-137.38-161.60
Sale Or Maturity of Investments75.0089.0486.14183.20177.9967.8354.55210.49239.44
Other Uses-0.83-0.830.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.0034.190.00
Cash from Investing Activities-43.5248.37-69.7746.2212.63-167.636.39105.689.37
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock116.730.0074.9426.8172.90239.667.810.21100.78
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock116.730.0074.9426.8172.90239.667.810.21100.78
Proceedsfrom Stock Options0.000.0074.9126.7172.74238.207.740.00100.20
Issuance or Reduction of Debt, Net0.000.000.000.000.00-11.4810.56-30.5229.26
Change in Long Term Debt0.000.000.000.000.00-11.4810.56-30.5229.26
Issuance of Long Term Debt0.000.000.000.000.000.0010.700.0029.91
Reduction of Long Term Debt0.000.000.000.000.00-11.48-0.14-30.52-0.65
Net Financing Active Other Cash Flow-2.87-5.86-0.41-0.10-0.03-3.120.000.00-1.78
Other Financing Activities Uses-2.87-5.86-0.41-0.10-0.03-3.120.000.00-1.78
Cash from Financing Activities113.86-5.8674.5426.7172.87225.0518.37-30.32128.26
Net Change in Cash-4.86-4.61-15.31-5.4017.935.29-13.87-21.0836.82
Free Cash Flow-75.31-47.22-20.20-79.63-68.17-52.44-39.09-98.06-102.17
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.00-0.370.000.00-0.180.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments114.2991.56105.4290.7595.9199.81
Short Term Receivables8.946.214.815.574.680.19
Inventories0.000.000.000.000.000.00
Other Current Assets0.000.000.000.000.004.20
Total Current Assets123.2397.77110.2396.32100.59104.20
Net Property, Plant & Equipment2.462.652.893.053.243.44
Total Investments and Advances90.3179.0685.3760.6171.3081.08
Other Assets0.150.210.230.490.410.42
Total Assets216.16179.69198.72160.46175.53189.15
Short Term Debt Incl. Current Port. of LT Debt0.610.590.570.550.530.52
Accounts Payable9.0715.5214.7313.169.198.80
Other Current Liabilities14.5412.1412.0714.9415.9117.53
Total Current Liabilities24.2228.2427.3728.6425.6326.84
Long Term Debt1.101.261.421.561.711.85
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities24.0325.6126.2927.1728.0928.72
Total Liabilities49.3655.1155.0757.3855.4357.41
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity166.80124.58143.65103.08120.10131.74
Total Shareholders Equity166.80124.58143.65103.08120.10131.74
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity166.80124.58143.65103.08120.10131.74
Total Liabilities & Stockholders Equity216.16179.69198.72160.46175.53189.15
Book Value Per Share1.110.891.030.861.111.22
Tangible Book Value Per Share1.110.891.030.861.111.22
Full-Time Employees---73--
Price to Book Ratio3.755.144.382.721.561.07
Return on Assets-40.66-41.07-35.11-34.10-79.17-76.90
Return on Equity-55.51-59.10-48.42-50.20-113.23-101.41
Return on Invested Capital-11.02-17.09-13.67-18.92-12.00-11.55
Quick Ratio5.093.464.033.363.923.88
Current Ratio5.093.464.033.363.923.88

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-18.51-21.50-19.82-19.80-14.61-15.43
Depreciation0.100.110.100.100.110.11
Other Funds (Non Cash)2.422.973.203.332.964.56
Funds from Operations-15.99-18.43-16.52-16.37-11.54-10.75
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-8.09-1.42-1.623.240.610.76
Cash from Operating Activities-24.08-19.85-18.15-13.13-10.93-9.99
Capital Expenditures-0.01-0.06-0.010.81-0.02-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-33.2010.32-30.9210.3913.855.07
Purchase of Investments-53.20-8.93-51.67-4.61-5.20-19.93
Sale Or Maturity of Investments20.0019.2520.7515.0019.0525.00
Other Uses0.000.000.00-0.830.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-33.2210.26-30.9310.3713.835.05
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock58.590.1158.030.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock58.590.1158.030.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.06-0.02-0.25-2.53-3.04-0.01
Other Financing Activities Uses-0.06-0.02-0.25-2.53-3.04-0.01
Cash from Financing Activities58.520.0957.78-2.53-3.04-0.01
Net Change in Cash1.23-9.498.70-5.30-0.15-4.96
Free Cash Flow-24.09-19.91-18.16-13.15-10.96-10.01

Revenue breakdown

United States2024: 18.72M 2025: 7.83M
Contract Research2024: 2.54M 2025: 1.87M
Dermatology Therapeutics2024: 16.18M 2025: 5.95M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.67%11.6M119.7M2.89M
2026-10-1513.53%15.0M111.1M2.67M
2026-09-3016.38%18.2M111.1M2.13M
2026-09-1514.13%16.1M113.7M2.09M
2026-08-3113.56%15.2M111.9M1.89M
2026-08-1413.14%14.7M111.9M1.76M
2026-07-3111.47%13.8M120.1M1.64M
2026-07-1511.72%13.4M114.0M1.62M
2026-06-3010.00%11.4M114.0M1.53M
2026-06-157.81%8.9M114.0M1.40M
2026-05-297.34%8.1M110.0M1.79M
2026-05-156.68%7.3M110.0M1.86M
2026-04-306.52%7.9M121.0M1.81M
2026-04-156.77%7.1M104.5M2.45M
2026-03-316.83%7.0M102.7M2.40M
2026-03-134.57%4.7M102.7M2.23M
2026-02-274.63%4.8M102.7M1.82M
2026-02-135.29%4.9M92.3M1.79M
2026-01-305.40%5.0M92.4M1.89M
2026-01-155.58%5.2M92.4M1.27M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.002.503.702.8111.3092.000.000.963-0.0260.001
call2.001.402.950.008.3570.000.000.925-0.0260.001
call3.000.801.750.854.01150.000.000.867-0.0230.001
call4.000.000.900.502.9132,0390.000.649-0.0290.002
call5.000.000.100.051.1829241.000.235-0.0140.002
call6.000.000.600.063.9201580.000.401-0.0530.003
call7.000.000.050.054.7992430.000.387-0.0680.003
call8.000.000.050.102.4602300.000.077-0.0120.001
call9.000.002.150.802.7504.000.000.071-0.0140.001
call10.000.002.150.053.0413.000.000.066-0.0150.001
put1.000.000.950.008.2850.000.00-0.038-0.0260.001
put2.000.000.750.054.66647.000.00-0.076-0.0250.001
put3.000.000.150.052.6641,5600.00-0.134-0.0220.001
put4.000.000.350.251.9792460.00-0.332-0.0280.002
put5.000.501.251.603.1411830.00-0.756-0.0130.002
put6.001.352.102.363.46147.000.00-0.671-0.0410.002
put7.002.303.502.175.68877.000.00-0.911-0.0120.001
put8.003.304.500.006.0980.000.00-0.922-0.0120.001
put9.004.305.500.006.5520.000.00-0.929-0.0130.001
put10.005.106.600.0010.7740.000.00-0.934-0.0120.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-27424B5SEC
2026-10-278-KCurrent report2026-10-27SEC
2026-09-21SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-01SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-048-KCurrent report2026-06-04SEC
2026-05-12SCHEDULE 13G/ASEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-04-288-KCurrent report2026-04-28SEC
2026-04-274Statement of changes in beneficial ownership of securities2026-04-27SEC
2026-04-27SCHEDULE 13G/ASEC
2026-04-23ARSAnnual report to security holders. 2025-12-31SEC
2026-04-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-04SEC
2026-04-07SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-04001.36M1
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.9.11%
BML Capital Management, LLC7.44%
BlackRock, Inc.7.19%
Deep Track Capital, LP6.69%
Vivo Capital, LLC4.79%
FMR LLC4.79%
VANGUARD CAPITAL MANAGEMENT LLC4.17%
Frazier Life Sciences Management, L.P.3.53%
Rock Springs Capital Management LP3.10%
ADAGE CAPITAL PARTNERS GP, L.L.C.2.91%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.04%
iShares Russell 2000 ETF2.22%
VANGUARD EXTENDED MARKET INDEX FUND1.04%
Fidelity Small Cap Index Fund0.93%
iShares Russell 2000 Growth ETF0.69%
iShares Biotechnology ETF0.56%
Select Biotechnology Portfolio0.53%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF0.52%
VANGUARD RUSSELL 2000 INDEX FUND0.46%
Fidelity Extended Market Index Fund0.42%

OakChart. ACRS. Cached 15 minutes.